- Home
- PAC vs NBIX Comparison
PAC vs NBIX Comparison
Compare PAC & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAC | NBIX |
|---|---|---|
| Founded | 1998 | 1992 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3B | 13.9B |
| IPO Year | 2006 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PAC | NBIX |
|---|---|---|
| Price | $283.53 | $124.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $270.00 | $177.38 |
| AVG Volume (30 Days) | 83.5K | ★ 1.2M |
| Earning Date | 02-24-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | 13.32 | ★ 41.95 |
| EPS | 1.07 | ★ 4.67 |
| Revenue | $1,870,491,921.00 | ★ $2,860,500,000.00 |
| Revenue This Year | $54.97 | $21.24 |
| Revenue Next Year | $11.83 | $8.59 |
| P/E Ratio | ★ $26.31 | $26.58 |
| Revenue Growth | ★ 35.46 | 21.45 |
| 52 Week Low | $168.62 | $84.23 |
| 52 Week High | $294.82 | $160.18 |
Technical Indicators
Market Signals| Indicator | PAC | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 30.94 |
| Support Level | $270.61 | $122.14 |
| Resistance Level | $294.82 | $142.82 |
| Average True Range (ATR) | 8.28 | 4.50 |
| MACD | -0.19 | -0.99 |
| Stochastic Oscillator | 53.53 | 9.59 |
Price Performance
Historical ComparisonAbout PAC Grupo Aeroportuario Del Pacifico
Grupo Aeroportuario del Pacifico SAB de CV is engaged in the construction, development, and operation of airports in Mexico. The company's segment includes Guadalajara; Tijuana; Puerto Vallarta; San Jose del Cabo; Montego Bay; Hermosillo; Guanajuato and Other Airports. It generates maximum revenue from the Guadalajara segment.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.